Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Miscellaneous >

Therapeutic Solutions International, Inc. (TSOI)

Add TSOI Price Alert      Hide Sticky   Hide Intro
Moderator: centsability4me
Search This Board: 
Last Post: 9/22/2017 9:44:40 AM - Followers: 79 - Board type: Free - Posts Today: 0

A public clinical stage company focused on immune modulation for the treatment of cancer and other specific diseases.

The Company’s corporate website is  New products can be viewed on and ordered at

Recent News:

Therapeutic Solutions Subsidiary, SandBox Dental Labs, files 510(k) with FDA

Therapeutic Solutions International Announces Exclusive Patent License Agreement with Subsidiary Emvolio, Inc.

Therapeutic Solutions files Patent on Methods of Re-Activating Dormant Memory Cells with Anticancer Activity

Therapeutic Solutions International Announces Exclusive Patent License Agreement with Subsidiary Emvolio, Inc.

Therapeutic Solutions files new Patent on Augmentation of Anti-Tumor Immunity by Mifepristone and Analogues Thereof

Therapeutic Solutions International Announces Exclusive Patent License Agreement to innaMune with its Subsidiary Emvolio, Inc.

Therapeutic Solutions files Patent on Blood Derived Innate Immune System Stimulator

Therapeutic Solutions International Announces Exclusive Patent License Agreement with its Subsidiary Emvolio, Inc.

Therapeutic Solutions files new Patent on Targeting the Tumor Microenvironment through Nutraceutical Based Immunoadjuvants

Therapeutic Solutions International Announces Appointment of Dr. Thomas E. Ichim to its Subsidiary Emvolio, Inc.

Therapeutic Solutions International's Subsidiary, Emvolio, Inc., Files Investigational New Drug Application for StemVacs Cancer Immunotherapy

Therapeutic Solutions International Announces Filing of new Immunotherapy Patent and Exclusive Patent License Agreement with Subsidiary Emvolio, Inc.

Therapeutic Solutions Receives Allowance on Patent Claim from the US Patent Office Covering ProJuvenol® Active Ingredient Pterostilbene in Cancer Immunotherapies

Therapeutic Solutions International Reports Augmentation of Cancer Immunotherapy Using Pterostilbene
Share Structure - 46M Float
Shares Outstanding 682,751,000 a/o July 31 , 2016
Float 46,312,028 a/o July 31 , 2016
Authorized Shares 995,000,000 a/o July 31 , 2016


Sandbox Dental Labs , Inc.

– is a majority owned subsidiary of TSI consisting of a dental laboratory to manufacture and fill prescriptions from dentists who will use our proprietary Sleep Appliance to treat their patients with mild to moderate obstructive sleep apnea.

Emvolio , Inc .

– is a majority owned subsidiary of TSI where the intellectual property surrounding immune-oncology is housed.  The Company is developing products that can be used together to attack cancer at different levels, as well as to be used alone or in combination with existing therapies.

Omnibiome , Inc .
– is a majority owned subsidiary of TSI where the intellectual property surrounding probiotics is housed. Current programs focus on the use of probiotics to prevent pre-term labor and on using probiotics to reverse periodontal disease.


Nutraceutical Division:
 – TSI has been producing very high quality nutraceuticals. Its flagship product, Projuvenol®, is a Patented (No. 9,682,047) proprietary mixture containing pterostilbene – one of the most potent antioxidants known.

Officers and Directors:

Timothy G. Dixon – President, CEO, & Chairman
Mr. Dixon currently serves as Chief Executive Officer, President, and Chairman of Therapeutic Solutions International, Inc. Mr. Dixon also serves as President and Chairman of OmniBiome, Inc. and President and Chairman of Emvolio, Inc. Mr. Dixon previously served as the President of TMD Courses, Inc. from 2006 to 2012 and; as the President of Splint Decisions Inc. from 2010 to 2011. 
Mr. Dixon has attended hundreds of hours of continuing medical/dental education throughout the years and has produced many educational DVD’s used by dental professionals worldwide on the subject of parafunctional control, migraine prevention, therapeutic Botox injections, migraine pathophysiology, dental sleep medicine, and other therapeutic protocols. Mr. Dixon also has extensive experience in dealing with corporate compliance matters with the U.S. Food and Drug Administration, (FDA) as well as many international regulatory bodies.
Gerry B. Berg – Vice President, CFO, Director
Gerry B. Berg has served as our Vice-President and Chief Financial Officer since April 20, 2011.  Mr. Berg also serves as Chief Financial Officer and Director of OmniBiome, Inc. and Chief Financial Officer  and Director of Emvolio, Inc. Mr. Berg became a director of the Company on August 24, 2012.  Mr. Berg has over 30 years of senior management experience working with private and public companies.  From May 2010 to March 2011, Mr. Berg served as President and Chairman of the Board of Directors of Friendly Auto Dealers, Inc., and also served in a consulting capacity from March 2009 to May 2010.
Mr. Berg holds a Bachelors of Science in Accounting from Walsh College where he graduated Cum Laude.  Mr. Berg became a Certified Public Accountant in the State of Michigan in 1979 and in the State of California in 1984.  Mr. Berg does not currently practice as a Certified Public Accountant.
Thomas E. Ichim, Ph.D – Director
Dr. Ichim was appointed to the Board of Directors on January 22, 2016.  Dr. Ichim also serves as Chief Executive Officer of Emvolio, Inc. Dr. Ichim is a seasoned biotechnology entrepreneur with a track record of scientific excellence. He has founded/co-founded several companies including Batu Biologics, Inc., Medvax Pharma Corp, ToleroTech Inc, bioRASI, and OncoMune LLC. To date he has published 99 peer-reviewed articles and is co-editor of the textbooks “RNA Interference: From Bench to Clinical Translation” and “Immuno-Oncology Text Book.”
Dr. Ichim is an ad-hoc editor and sits on several editorial boards. Dr Ichim is inventor on over 50 patents and patent applications. Dr. Ichim has extensive experience with stem cell therapy and cellular product development through FDA regulatory pathways. Dr. Ichim spent over 7 years as the President and Chief Scientific Officer of Medistem, developing and commercializing a novel stem cell, the Endometrial Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through Phase II clinical trials with the FDA. Dr. Ichim has extensive experience in product development, regulatory filings, and business development.
Dr. Ichim has a BSc in Biology from the University of Waterloo, Waterloo, Ontario, Canada, a MSc in Microbiology and Immunology a University of Western Ontario, London, Ontario, Canada and a Ph.D in Immunology from the University of Sciences Arts and Technology, Olveston Monserrat.

Hong Ma, MD, Ph.D., M.B.A. – Chief Scientific Officer
Dr. Ma has an extensive history in academic and translational research. Subsequent to completing her medical degree, she performed basic research in the area of molecular biology of endothelial-associated pathways in her doctorate and postdoctoral studies. She has been critical in establishing numerous ventures and collaborations in the area of biosciences. Dr. Ma has over 20 peer-reviewed publications and has worked with prestigious institutions in the USA, China, and Japan. She received her M.D. from Dalian Medical University, her Ph.D in Cardiovascular Pharmacology at Asahikawa Medical College, and has also earned her MBA at the Rady School of Management at the University of California San Diego.

Contact :
CEO email address:  

Therapeutic Solutions International, Inc.
4093 Oceanside Blvd Suite B
Oceanside CA 92056

IR Email:


Disclaimer : All of the information presented in the IBOX , Stickies , or posts of  individual opinions , should not be considered as recommendations to buy , sell , or hold this stock .

Cannabis Stocks News
Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TSOI News: Quarterly Report (10-q) 08/14/2017 03:57:02 PM
TSOI News: Therapeutic Solutions International Returns to Fully Reporting Status with SEC 07/06/2017 09:00:00 AM
TSOI News: Quarterly Report (10-q) 07/05/2017 01:06:35 PM
TSOI News: Therapeutic Solutions Subsidiary, SandBox Dental Labs, files 510(k) with FDA 06/26/2017 09:00:00 AM
TSOI News: Current Report Filing (8-k) 06/12/2017 05:02:31 PM
#5758   TSI Patent Update Info centsability4me 09/22/17 09:44:39 AM
#5757   a lot of centsability4me 09/21/17 02:12:11 PM
#5756   Could it be that it's just too much Tv23 09/20/17 01:55:17 PM
#5755   mv was around 5M centsability4me 09/20/17 01:15:58 PM
#5754   Re: TSI's CoQ10 centsability4me 09/20/17 01:04:25 PM
#5753   Ron Irwin article on OMNI centsability4me 09/15/17 10:32:09 AM
#5752   Gilmer Knows centsability4me 09/11/17 11:53:00 AM
#5751   Good morning TSOI!!! Looks like somebody knows something! Harbintown 09/11/17 11:40:44 AM
#5750   CENTS... let's hope !!! corvatsch 09/08/17 03:14:48 PM
#5749   Hmmmmmmmmm Clinical trials where JWCI pardners ? centsability4me 09/08/17 02:26:55 PM
#5748   L.A. Post-Examiner write-up by Ron Irwin on TSI centsability4me 09/07/17 09:01:55 AM
#5747   TSI mentioned in S M Observer centsability4me 09/06/17 10:53:53 AM
#5746   ProJuvenol® Patent No.: 9,682,047 centsability4me 07/30/17 11:23:39 PM
#5745   Internationally Known Cancer Expert is Behind TSOI Cancer Technology Biotechupdates 07/27/17 02:11:57 PM
#5744   TSI now fully reporting centsability4me 07/06/17 01:18:11 PM
#5743   $TSOI Therapeutic Solutions Subsidiary, SandBox Dental Labs, files $Pistol Pete$ 06/27/17 07:28:42 AM
#5742   Sandbox Dental Website: centsability4me 06/26/17 07:40:29 PM
#5741   NEWS 6/26/17 centsability4me 06/26/17 09:04:01 AM
#5740   guess I'm here tomorrow JackAskSlap 06/22/17 08:15:11 PM
#5739   Re: TSI Projuvenol Patent centsability4me 06/20/17 01:42:32 PM
#5738   "We're in research, centsability4me 06/20/17 01:25:24 PM
#5737   cancer therapies in the news : centsability4me 06/19/17 12:10:55 PM
#5736   PR 6/12/17 centsability4me 06/12/17 09:29:57 AM
#5735   GLTA , centsability4me 06/11/17 01:16:05 PM
#5734   More on Dr. Glassman centsability4me 06/08/17 09:18:52 AM
#5733   From the 10 K : centsability4me 06/08/17 08:58:12 AM
#5732   10K Link to filing: centsability4me 06/07/17 01:31:24 PM
#5731   Therapeutic Solutions files Patent on Methods of Re-Activating Caveat Emptor 06/05/17 09:28:12 AM
#5730   NEWS 6/5/17 centsability4me 06/05/17 09:02:53 AM
#5729   Thanks for your info/assessment. I will keep this rakp 06/02/17 10:16:14 AM
#5728   Who really knows? centsability4me 06/02/17 08:29:16 AM
#5727   Why is there so little/no interest in this company? rakp 06/01/17 07:41:31 PM
#5726   8K OUT centsability4me 06/01/17 04:17:37 PM
#5725   NEWS 6/1/17 centsability4me 06/01/17 09:03:11 AM
#5724   here is an article about centsability4me 05/27/17 12:09:24 AM
#5723   Just noticed 3 blank spaces under centsability4me 05/26/17 10:13:56 AM
#5722   Cor, accumu @ low PPS is only for the centsability4me 05/24/17 12:16:29 PM
#5721   0,0083 $.... - 8% corvatsch 05/23/17 02:39:42 PM
#5720   ***NEWS 5/22/17*** centsability4me 05/22/17 09:03:23 AM
#5719   8K Out centsability4me 05/18/17 08:56:35 PM
#5718   no volume, no party... corvatsch 05/18/17 02:32:44 PM
#5717   ***NEWS 5/18/17*** centsability4me 05/18/17 09:03:21 AM
#5716   ***NEWS 5/16/17*** centsability4me 05/16/17 09:05:21 AM
#5715   The share structure centsability4me 05/16/17 08:59:09 AM
#5714   the filings should provide you centsability4me 05/14/17 12:13:03 AM
#5713   The team looks very impressive. Gan 05/13/17 05:22:01 PM
#5712   TSOI latest FAQ centsability4me 05/11/17 11:58:52 AM
#5711   stervc, thanks ! centsability4me 05/11/17 09:31:36 AM
#5710   centsability4me, here with TSOI... stervc 05/11/17 08:07:21 AM
#5709   8K OUT centsability4me 05/10/17 06:38:12 PM